Pfizer starts Phase 2/3 study of oral antiviral drug for adults after COVID-19 exposure

Pfizer’s study will evaluate the investigational novel oral antiviral candidate PF-07321332 for the prevention of illness in adults living in the same household as someone with COVID-19.

Read the full article here

Related Articles